Q-omics provides the consensus-scored FAM90A20P profile across patient tissues and cancer cell-line models. FAM90A20P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM90A20P is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, FAM90A20P RNA expression shows 15,299 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, BRCA, and THYM as cancer lineages where FAM90A20P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM90A20P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM90A20P survival associations across molecular data types. FAM90A20P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM90A20P RNA expression–survival associations across cancer types. High FAM90A20P expression shows unfavorable associations in DLBC, THCA, KIRC and LGG, but favorable associations in HNSC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM90A20P RNA expression.
This table summarizes FAM90A20P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM90A20P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM90A20P shows lower tumor expression in BRCA, THCA and UCEC and higher tumor expression in KIRC, CHOL and KICH. The BRCA box plot shows higher FAM90A20P RNA expression in normal versus tumor tissue (log2 FC = −0.178, t-test p < 0.001).
This table shows molecular features associated with FAM90A20P in patient tissues and cancer cell lines. In patient samples, FAM90A20P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
